📁Pharma Team / Shared drive

Covers top 25 commercial plans + Medicare Part D. Net price erosion modeled at 4-6% post-IRA. UHC remains highest-leverage negotiation.

Cigna win (+14.1M lives) this week. YTD net change: +23.5M lives across 18 wins, offset by 2 losses + 1 step-edit imposition.

Top objection remains budget impact at year 2. Approved counter-evidence: BIM v4, real-world Optum claims cohort (n=12,400).

Zenvara crosses small-molecule 7-year threshold January 2032. Modeled MFP outcomes 38-52% off WAC. NPV impact -$1.2B to -$0.4B over 5 years.